Kam Kalantar-Zadeh

APABETALONE (AN EPIGENETIC BET-INHIBITOR SMALL MOLECULE) AND EFFECTS ON COGNITION IN DIABETES PATIENTS WITH CARDIOVASCULAR DISEASE

population had DDIs (average of 7.12 per person, SD 6.7), and 37% had DGIs (average of 1.98 per person, SD 1.3). 9% of the population had an ACB score of three or higher. The algorithm then provided actionable advice for physicians to revise medication issues. Conclusions:MM is a complex task, amplified when dealing with an older population who are not only on more medications, but also have existing comorbidities and alternate pharmacokinetics. CDSS can better enable MM, through its ability to consider a full list of medications, comorbidities, and complex medical recommendations (such as Beers Criteria), reduce redundancies, reduce DDIs and DGIs, and recommend better alternatives. CDSS can generate effective and highly-usable guidelines for each recommended change (deprescribing methodologies, changing dosages or formulations, replacing with alternatives, and scheduling). Continued study of the impact of medications on this population with cognitive decline is warranted.